MedTrace Logo

A Study to Investigate the Efficacy, Safety and Tolerability of PEG in Patients With Genital Herpes

NCT01765114 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2014-08-05

No results posted yet for this study

Summary

The aim of this study is therefore to investigate the efficacy of the PEG-formulation to reduce the frequency and duration of genital herpes recurrences, to assess its safety and tolerability and to investigate its effect on shedding.

Conditions

  • Genital Herpes

Interventions

DRUG

PEG-Formulation

Sponsors & Collaborators

  • Devirex AG

    lead INDUSTRY

Principal Investigators

  • Thomas Kuendig, MD · University of Zurich

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-02-28
Primary Completion
2014-08-31
Completion
2014-08-31

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01765114 on ClinicalTrials.gov